The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Advancements in second-line immunotherapy for cholangiocarcinoma
Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, discusses second-line therapies and immunotherapies for cholangiocarcinoma. Currently, the standard first-line treatment includes nivolumab or pembrolizumab with chemotherapy. If the disease progresses, second-line therapies such as FOLFOX are used in the absence of genetic alterations. It is emphasized that the next step should be to develop new regimens that incorporate immune checkpoint inhibitors in this line of treatment. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
